G1 Therapeutics Provides First Quarter 2022 Financial Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
G1 Therapeutics (GTHX) PT Lowered to $42 at Needham & Company
May 4, 2022 3:51 PM EDTNeedham & Company analyst Gil Blum lowered the price target on G1 Therapeutics (NASDAQ: GTHX) to $42.00 (from $44.00) while maintaining a Buy rating following earnings.
The analyst commented, "G1 reported COSELA sales of $5.5M, ~24% q/q increase. G1's internal sales team was... More
